Treatment by asenapine for 5weeks decreases weight and triglycerides levels of Wistar rats

Brito, Rodrigo Bernini de; Ghedini, Paulo César

doi:10.1016/j.schres.2014.02.002

Cited by 2 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 22 In rats, treatment with asenapine for 5 weeks decreases weight and triglyceride levels. 23 In short- and long-term clinical studies, asenapine was well tolerated and carried a lower risk of weight gain and metabolic abnormalities than olanzapine in adult patients with schizophrenia or bipolar I disorder. 18 , 24 Further, Bak et al have shown that a significant proportion of patients may experience >7% weight loss after starting asenapine without showing a duration response pattern.…”

Section: Discussionmentioning

confidence: 97%

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report

Okazaki

Yamamuro

Kishimoto

2017

NDT

View full text Add to dashboard Cite

AimsAntipsychotics are effective for treating schizophrenia, but atypical antipsychotics can cause several adverse side effects including weight gain, hyperprolactinemia, and extrapyramidal symptoms. Moreover, weight gain increases the risk of metabolic diseases.MethodsWe treated a case of olanzapine-induced weight gain in a 41-year-old man with schizophrenia by switching his medication from olanzapine to asenapine.ResultsThe weight gain improved after switching the medication, from 80.3 to 75.0 kg, a weight loss of 6.6%, and there was no significant worsening of psychological symptoms or other adverse effects.ConclusionsAsenapine might be effective for treating patients with schizophrenia who experience olanzapine-induced weight gain.

show abstract

Section: Discussionmentioning

confidence: 97%

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report

Okazaki

Yamamuro

Kishimoto

2017

NDT

View full text Add to dashboard Cite

show abstract

“…Based on the literature data, however, ASE, used in the present study, seems to have a relatively low weight gain liability and according to a recent metaanalysis, it produces only low weight gain. In rats, a weight loss was observed both five weeks after ASE treatment and after combined treatment of ASE with hypercaloric diet (de Brito and Ghedini, 2014). CMS -stress preconditioned Fadel et al (2002) have shown that weight gain is as sociated with activation of a distinct population of Hcrt neurons.…”

Section: Discussionmentioning

confidence: 99%

“…However, ASE seems to have a relatively low weight gain liability for an atypical antipsychotic (which are notorious for their metabolic side effects) and according to a recent metaanalysis it produces significantly less weight gain. In rats, a weight loss has been observed five weeks after ASE treatment as well as combined treatment of ASE with hypercaloric diet (de Brito and Ghedini, 2014). In mice with experimentally destroyed Hcrt cells, a signifi cant increase in body weight has been demonstrated (Hara et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

Effect of Asenapine on the Activity of Hypocretin Neurons in Normal and Unpredictable Mild Stress Preconditioned Rats

Majercikova,

Kiss

2015

Fol. Biol.

View full text Add to dashboard Cite

Asenapine (ASE) is a novel atypical antipsychotic used in schizophrenia treatment. Here, the effect of ASE on Fos expression in hypocretin (Hcrt) neurons in medial and lateral portions of the lateral hypothalamus (LH) and the effect of chronic unpredictable variable mild stress (CMS) preconditioning were studied. CMS consisted of restraint, social isolation, crowding, swimming, and cold and lasted 21 days. The rats were sacrificed on day 22, 90 min after a single injection of vehicle (saline 300 μl/rat subcutaneously – s.c.) or ASE (0.3 mg/kg s.c.). Control (CON), ASE, CMS, and CMS + ASE groups were used. Fos protein was visualized by the avidin biotin peroxidase technique, while Hcrt perikarya by fluorescent dye. Fos/Hcrt co-localizations were evaluated under parallel light and fluorescent illuminations. In the single Fos expression assessment, the Fos number was significantly higher in the medial in comparison with the lateral LH portion in each group. No differences in Fos amount were observed between the individual groups within the medial and lateral LH portions. In the Fos/Hcrt co-localization assessments, ASE significantly reduced the number of Fos/ Hcrt neurons in the medial, but not lateral, LH portion in ASE and CMS + ASE groups. CMS only slightly contributed to the inhibitory effect of ASE in the CMS + ASE groups. The present data show as the first that ASE may reduce the activity of Hcrt cells in the medial LH portion, which might correspond with the relatively low weight gain liability of ASE. CMS preconditioning did not significantly interfere with this impact of ASE.

show abstract

Treatment by asenapine for 5weeks decreases weight and triglycerides levels of Wistar rats

Cited by 2 publications

References 11 publications

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report

Effect of Asenapine on the Activity of Hypocretin Neurons in Normal and Unpredictable Mild Stress Preconditioned Rats

Contact Info

Product

Resources

About